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A B S T R A C T
There is raising evidence reporting an increased incidence of breast cancer over the past decades. Every
year approximately 1.4 million new cases of breast cancer are diagnosed worldwide, with a mortality rate
of approximately 450,000/year. Out of these cases, 6.6% are diagnosed in premenopausal women with a
median age at diagnosis of 40 years: in premenopausal women breast cancer seems to be more aggressive
than in post-menopausal women. Obesity has been reported to increase the risk of developing breast
cancer and to worsen the prognosis. This seems to be due to several obesity-related mechanisms. Insulin
resistance that often occurs with obesity may results in compensatory hyperinsulinemia. Insulin cross-
binds insulin-like growth factor-I receptors expressed on breast cells, resulting in proliferative stimuli on
breast cancer cells. Besides, hyperinsulinemia up-regulates the growth hormone receptor (GHR) thus
increasing GHR stimulation and resulting in an increased hepatic IGF-I synthesis. Moreover, insulin
decreases the hepatic expression of binding proteins of IGF-I, such as insulin-like growth factor binding
proteins (IGFBP)-1 and IGFBP-2, thus leading to high circulating and bioavailable free IGF-I. Additionally,
obesity is associated to chronic low-grade inﬂammation that has been reported to be an additional
stimulus for tumor growth. This review shows the current evidence regarding to the association of
obesity and breast cancer in premenopausal state focusing on both human and basic studies; showing
that the obesity is a risk factor for breast cancer also among premenopausal women, especially for the
molecular subtype Triple Negative Breast Cancer.
© 2018 Published by Elsevier B.V.
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Breast cancer (BC) is a growing public health problem. Although
current efforts in preventing BC, the incidence is increasing in most
developed and developing countries [1–4]. Each year about 1.4
million new cases of BC are diagnosed worldwide, with a mortality
rate of approximately 450,000/year [5]. Of these, 6.6% areAbbreviations: BC, breast cancer; BMI, body mass index; TNBC, Triple Negative
Breast Cancer; GHR, growth hormone receptor; IGF-1, insulin-like growth factor-I
IGFBP Factor Binding Protein; ER, estrogenreceptor; IL, interleukin; NF-kB, nuclear
factor-kappa B; MMP-9, metalloproteinase-9; MCP-1, monocyte chemoattractant
protein-1; HIF-1, hypoxia inducible factor-1; PI3K, phosphatidylinositol 3-kinase;
Akt, protein kinase B; MAPK, mitogen-activated protein kinase; VEGF, vascular
endothelial growth factor.
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0301-2115/© 2018 Published by Elsevier B.V.diagnosed in premenopausal women, with a median age at
diagnosis of 40 years [6,7]. In premenopausal women BC seems to
be more aggressive than in post-menopausal women, showing
higher histological grading, increased proliferation rate, higher
rates of vascular invasion [8] and a higher proportion of triple-
negative breast cancer (TNBC) [9]. Further, BC in premenopausal
women has been associated to an increased risk of recurrence and
mortality rate compared to postmenopausal women [9,10]. Several
risk factors for BC have been identiﬁed, such as age, genetic
mutations (BRCA 1 and BRCA 2) [11], younger age at menarche, ﬁrst
pregnancy after the age 30, nulliparity, older age at menopause,
dense breast tissue [12], hormone replacement therapy, use of oral
contraceptives [13], personal and family history of BC or other
breast diseases [14]. Recently, it has been also highlighted that
obesity could represent an important risk factor of developing BC
[15,16]. This seems to be due to several metabolic derangements
associated to obesity. First, obesity is often associated to insulin
resistance that could result in secondary hyperinsulinemia with
consequent cross-binding of insulin-like growth factor-I (IGF-I)
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neoplastic breast epithelial cells [17]. Furthermore, obesity has
been associated to a subclinical, chronic, low-grade inﬂammation
that represents an additional predisposing factor for cancer [18].
Thus, the aim of this manuscript is to provide a general overview of
the current evidence on the association of BC and obesity in
premenopausal state, reviewing both clinical and basic studies.
Obesity and Breast Cancer
Clinical evidence
Several studies investigated the association between obesity
and BC [19–21], providing conﬂicting results [22,23]. In a
longitudinal study Michels et al. reported an inverse association
between body mass index (BMI) and the risk of BC (p < 0.001) in
premenopausal women [22]. The women included in the study
aged 25–42 years and were asked to reply to a self-administered
questionnaire about their medical history and lifestyle. They were
followed for 14 years and were asked to update questionnaires
information on demographic variables, lifestyle factors, and
medical events every two years. This study reported interesting
result but the self-administration of the questionnaire represents
an important bias [22]. Same results were reported by Cecchini
et al. in a chemoprevention study ﬁnding that BMI had a signiﬁcant
relation with increased risk of BC among premenopausal women
>35 years of age, although this result was not conﬁrmed in
postmenopausal women [23]. This study used data from the
National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1
(Breast Cancer Prevention Trial) and STAR (Study of Tamoxifen and
Raloxifene) that were 2-arms, double-blinded, randomized clinical
trials investigating the use of chemoprevention for BC. The women
included in the study were aged >35 years, did not have history of
invasive BC but presented a high risk of developing BC evaluated by
Gail score (Gail score  1.66). Increased risk of invasive BC was
signiﬁcantly associated with high BMI (p = 0.01) in premenopausal
women [23]. Furthermore, the authors found a statistically
signiﬁcant association between BMI and estrogen receptor (ER)-
positive BC, with hazard ratios for the 2 upper categories of BMI of
1.41 and 1.78 (p = 0.04) [23]. This trend was not conﬁrmed for ER-
negative BC and this could be due to the small number of BC events
in this group. In this study, however, the assessment of BMI was
performed only at the study beginning so preventing to draw ﬁrm
conclusions on the long-term effect of high BMI [23]. The effect of
obesity on premenopausal BC risk differs across disease subtypes.
Several studies have reported a positive association between
obesity and the risk of developing TNBC in premenopausal women
[24–26]. TNBC subtype is particularly aggressive and frequently
occurs in premenopausal women [24,26,27]. In a recent retro-
spective study, Sahin et al. evaluated the association between BMI
and immunohistochemical subtypes in BC for premenopausal and
postmenopausal women [25]. In the study population BMI was
stratiﬁed into 3 groups according to BMI as normal-weighted (BMI
<25 kg/m2), over-weighted (BMI 25–29.9 kg/m2), and obese (BMI
30 kg/m2), immunohistochemical classiﬁcation of the tumors was
categorized into 4 groups: luminal-like, HER2/luminal-like, HER2-
like, and TNBC according to the ER/PR and HER2 status. This study
demonstrated that there was a high prevalence of obesity at
diagnosis of BC in both premenopausal and postmenopausal
women (p < 0.001 and p < 0.001, respectively) TNBC subtype was
signiﬁcantly more common in obese premenopausal women
compared to women with BMI <30 kg/m2 (p = 0.007). In addition,
obese premenopausal patients experienced less common luminal-
like subtype (p = 0.033), and more frequently presented with
higher tumor stage (p = 0.012) and tumor grade (p = 0.004) at
diagnosis when compared to patients with BMI <25 kg/m2 [25].These data conﬁrm the results obtained by a case–case study,
which has reported the positive association of risk for TNBC with
both weight and BMI in premenopausal women (p = 0.012 and
0.004, respectively) with a 5% increase in risk observed for 5 kg
increase in weight and a 16% increase in risk per 5 kg/m2 increase in
BMI [26]. The Cancer and Steroid Hormone (CASH) population-
based, case-control study, found an increased risk for TNBC in
premenopausal women reporting a strong positive association
between BMI and premenopausal TNBC risk (OR (odds ratio) = 1.67,
95% CI (conﬁdence interval) 1.22–2.28; p = 0.026) [28]. Conversely
Yang et al. reported that obesity in younger women was associated
with an increased risk of developing ER-positive or PR-positive
tumors rather than TNBC suggesting that BMI seems to be more
associated with hormone receptor positive tumors [29]. However,
the results of this study were limited by the fact that data were
pooled from different studies that were not totally comparable in
terms of enrolled subjects and experimental design [29]. The
association between BC and obesity seems to be mediated by intra-
abdominal visceral fat that is the main responsible for obesity-
related metabolic and hormonal changes promoting the develop-
ment of BC [30]. Another prospective study, evaluated the
association between abdominal fat, measured as waist and hip
circumferences and by the waist-to-hip ratio, and the risk of BC in
premenopausal women [31]: 116.430 women were included and
during a 12-years follow up 630 cases of premenopausal invasive
BC were recorded. Abdominal adiposity was not signiﬁcantly
associated with overall incidence of premenopausal BC: however,
but adiposity was associated with risk of developing of ER-negative
BC more strongly than with the risk of ER–positive BC. Although
these results were promising, they should be interpreted with
caution due to the fact that the assessment of anthropometric
measurements was self measured by the patients. Further, the
measurement of waist circumference is an indirect measurement
of visceral adipose tissue, not providing an accurate evaluation
[31]. Further research with more detailed measurements of
abdominal fat with methods not investigator-dependent is
required to elucidate the exact role played by total and abdominal
fat mass in determining BC risk so identifying potential targets for
treatment intervention.
Pathogenesis
Several mechanisms are involved in the association of obesity
and increased risk of developing BC. In lean premenopausal
women, estrogens are mainly produced by ovarian granulosa cells
and only a little part is produced by other peripheral tissues
especially the adipose one [32] while in obese premenopausal
women, most of estrogens derive from the conversion of
androgens into estrogens by aromatase in the adipose tissue
[32]. High levels of estrogens released into the circulation from the
adipose tissue activate the negative feedback in the hypothalamus
pituitary axis leading to reduced gonadotrophin secretion [33],
thus resulting in amenorrhea and reduced ovarian activity with a
markedly reduced synthesis of progesterone [34]. Initially, this
mechanism has been considered as protective against the risk of BC
in obese premenopausal women, because it was hypothesized that
progesterone would increase proliferation of breast cells in the
luteal phase when progesterone levels are usually high [35].
However, this theory has not been supported by subsequent
studies that have hypothesized that progesterone is neutral or even
protective for BC [36]. In fact it has been hypothesized to either
decrease BC risk, by mitigating the estrogen-induced proliferation
in breast epithelial cells [37]. Cohort studies have examined
circulating progesterone levels and BC risk in premenopausal
women and have reported inverse association between circulating
progesterone levels and risk of BC. The European Prospective
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association between sex steroid hormones and BC occurrence in
premenopausal women, reporting a statistically signiﬁcant inverse
relationship between serum levels of progesterone and BC
incidence OR for highest versus lowest quartile (OR = 0.61, 95%
CI = 0.38–0.98; p = 0.06) [38]. In another prospective nested case-
control study Schernhammer et al. have investigated the associa-
tion between circulating sex steroids and BC risk in premenopausal
women ﬁnding that endogenous progesterone was not statistically
associated with BC (OR, 1.16; 95% CI, 0.60–2.27; p = 0.75) [39]. In
addition to hormonal mechanisms, metabolic factors have been
hypothesized to be involved in the link between obesity and BC.
Several studies have conﬁrmed that insulin resistance and
compensatory hyperinsulinemia have been associated with
increased risk of BC and with a worse prognostic outcomes both
in premenopausal and postmenopausal women [40–43]. IGF-I
receptors are the main mediators of proliferative effects of insulin.
This could be due to the high homology (more than 50%) of the
insulin receptor (IR) and IGF-I receptor (IGF-IR) that is even 84% at
the a-subunit of the tyrosine kinase domain [44]. Further, insulin
and IGF-I share 40–50% homology. Because of this, insulin and IGF-
I can interact either with IR or with IGF-IR [45], and both of these
receptors have been associated with tumor development [46]. It
has also been reported an overexpression of IGF-IR in BC that is
functional for establishing an enhanced anabolic state necessary
for cell proliferation, differentiation, and anti-apoptosis via
deregulating or over-activating multiple downstream signaling
pathways, including the phosphatidylinositol 3-kinase (PI3K)/
protein kinase B (Akt) and mitogen-activated protein kinase
(MAPK) pathways. This overexpression seems to be stimulated by
high IGF-I and insulin levels [47–49]. Instead, the indirect effects of
hyperinsulinemia on carcinogenesis are attributable to the action
of insulin on circulating endogenous growth factors and their
binding proteins. In hyperinsulinemic states, the growth hormone
receptor (GHR) is upregulated by the increase of insulin concen-
trations in portal circulation thus the increase of GHR stimulationFig. 1. Potential Mechanisms of obesity leading to cancer development. Schematic repre
may promote, directly and indirectly, breast cancer growth. IGF-1: insulin-like growth fac
protein; IGFBP 1/2: insulin-like growth factor binding protein 1/2; IL-1b: interleukin-1result in an increased hepatic IGF-I synthesis [50]. Moreover,
insulin decreases the hepatic expression of binding proteins of
IGF-I, such as insulin-like growth factor binding proteins (IGFBP)-1
and IGFBP-2 [51], thus leading to high plasma levels and
bioavailability of free IGF-I [52]. In this context, IGFBP-1 inhibits
the growth of BC cells in mice with MCF-7 BC xenografts, as well as
hepatocellular cancer growth in mice over-expressing IGF-I and
IGF-II [53,54]. Additionally, obesity is accompanied by increased
circulating levels of pro-inﬂammatory mediators, such as inter-
leukin (IL)-6, tumor necrosis factor alpha (TNFa), matrix metal-
loproteinase (MMP)-9 and IL-1b, that have been reported to
promote tumorigenesis [55]. Additionally obesity enhances the
secretion of monocyte chemo-attractant protein (MCP)-1, which
stimulates the recruitment of macrophages to adipose tissue,
including the breast one. These tumor-associated macrophages
likely contribute to tumor growth by increasing local and/or
systemic inﬂammatory and angiogenic factors and generating
reactive oxygen species [56]. Thus, the increase of pro-inﬂamma-
tory cytokines secretion creates a favorable environment inducing
tumor cells to acquire a phenotype with major invasiveness and
aggressiveness [57–60] (Fig. 1). Furthermore, the progressive
hypertrophy of white adipocytes and the expansion of the white
adipose tissue make the same adipocytes more away from the
vascular network, with the reduction of the oxygen availability
[61]. In hypoxia state the adipose tissue generates an increased
state of oxidative stress, able to make the white adipocytes
hypertrophic/hypoxic and to secrete inﬂammatory proteins and to
induce brown adipocytes dysfunction [62]. Hypoxia, furthermore,
induces a status of insulin resistance [63,64], ischemia and
necrosis of white adipocytes [65]; production and release of
inﬂammatory cytokines and angiogenic factors [66]. The decrease
oxygen tension activates the transcription factor hypoxia inducible
factor (HIF)-1 generating a series of negative effects as inhibition of
production of adiponectin by white adipocytes and increased level
of leptin [67]. In fact adiponectin appears to have a regulatory role
in insulin resistance and to exert antineoplastic activities, asentation of aspects of obesity that shows how insulin resistance and inﬂammation
tor-1; IR-A: insulin receptor type A; IR-B: insulin receptor type B; SHBG: sex binding
 beta; IL-6: interleukin-6; TNF-a: tumor necrosis factor-alpha.
Fig. 2. Potential mechanisms of obesity leading to cancer development. Schematic representation of aspects of obesity that shows how the changes in adipose tissue during
weight gain. During obese adipose tissue expansion, preadipocyte differentiation is impaired, and hypoxia activates hypoxia-inducible factor 1 (HIF-1) with consequently
decrease adiponectin expression and upregulat leptin, secretion of inﬂammatory cytokines, including tumor necrosis factor a (TNF-a), interleukin-6 (IL-6), induction a status
of insulin resistance and icreased of oxidative stress.
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and tumor cells [68]. In addition, adiponectin has been reported to
block angiogenesis by decreasing the expression of vascular
endothelial growth factor (VEGF) and Bcl-2 (anti-apoptotic) and
increasing the activity of p53, Bax and caspase (pro-apoptotic),
with resulting in apoptosis of endothelial cells. Likewise,
adiponectin was shown to reduce TNF-a induced effects on cell
proliferation and migration [69,70]. Conversely low levels of
adiponectin exert pro-inﬂammatory effects rising the secretion of
several proinﬂammatory cytokines including TNF-a and IL-6,
leading to the onset of a tumorigenic microenvironment promot-
ing tumor development [71]. Leptin, closely related to adipose
tissue mass and volume of adipocytes [72], has instead been shown
to have carcinogenic properties, increasing the expression of anti-
apoptotic proteins, inﬂammatory markers (TNF-a, IL-6), angio-
genic factors (VEGF), and also the hypoxia-inducible factor-1a
(HIF-1a) by promoting cancer cell survival, proliferation and
migration [73]. (Fig. 2).
Conclusion
Epidemiological studies indicate progressively increased number
of cases with BC in most developed and developing countries.
Premenopausal state at diagnosis is highly associated with a
signiﬁcantly increased risk of recurrence and higher mortality rate.
Obesity has been reported to be a risk factor for BC, especially for the
molecular subtype TNBC. The effects of obesity on the risk of breast
cancer in premenopausal are mediated by molecular mechanisms as
compensatoryhyperinsulinemia to insulinresistance andhighlevels
of insulinand IGF-1, increased pro-inﬂammatorycytokines secretion
(TNF-a and IL-6), changes in the leptin and the hypoxia. This
information is important either for Oncologist and Nutritionists to
increases the knowledge on the possible relationships between
obesity and breast cancer in premenopausal women, with the aim
not only to reduce the risk of breast cancer in obese patient but also
for delineating the risk proﬁle for metabolic risk factors that may
result from obesity. Being obesity a multifactorial disease and an
important risk factor for BC, further study should be focused to
implement individual lifestyle recommendations based on both
prevention of cancer risk and weight management.References
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